Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

476275 Myricetin - CAS 529-44-2 - Calbiochem

A cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties.

Myricetin - CAS 529-44-2 - Calbiochem: MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.

Sinonimi: 3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II

476275
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
529-44-2C₁₅H₁₀O₈

Products

Numero di catalogoConfezionamento Qtà/conf
476275-25MG Fiala di plastica 25 mg
Description
OverviewA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki = ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
Catalogue Number476275
Brand Family Calbiochem®
Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
References
ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
Strobel, P., et al. 2005. Biochem. J. 386, 471.
Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
Walker, E.H., et al. 2000. Mol. Cell 6, 909.
Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
Product Information
CAS number529-44-2
FormYellowish brown solid
Hill FormulaC₁₅H₁₀O₈
Chemical formulaC₁₅H₁₀O₈
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numero di catalogo GTIN
476275-25MG 04055977184471

Documentation

Myricetin - CAS 529-44-2 - Calbiochem MSDS

Titolo

Scheda di sicurezza (MSDS) 

Myricetin - CAS 529-44-2 - Calbiochem Certificati d'Analisi

TitoloNumero di lotto
476275

Riferimenti bibliografici

Panoramica delle referenze
Lee, K.W., et al. 2007. Carcinogenesis 28, 1918.
Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
Strobel, P., et al. 2005. Biochem. J. 386, 471.
Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
Walker, E.H., et al. 2000. Mol. Cell 6, 909.
Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision21-November-2008 JSW
Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
DescriptionA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
FormYellowish brown solid
Intert gas (Yes/No) Packaged under inert gas
CAS number529-44-2
Chemical formulaC₁₅H₁₀O₈
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (5 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
Strobel, P., et al. 2005. Biochem. J. 386, 471.
Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
Walker, E.H., et al. 2000. Mol. Cell 6, 909.
Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.